Myasthenia gravis is a chronic disorder, which is triggered by defect in neuromuscular transmission. Individuals with myasthenia gravis struggle with a type of muscular tissue disorder that triggers when communication between the nerve and muscle is interrupted at the neuromuscular junction-the place where nerve cells connect with the muscles they control. Japan is presently the second-largest market for myasthenia gravis treatment and is expected to reach a value of $708.5 million by 2028.
The Japan myasthenia gravis treatment market is anticipated to be driven by factors such as increase in prevalence of the myasthenia gravis among individuals. In addition, the authorization of unique drugs by the Pharmaceuticals and Medical Devices firm (PMDA) is expected to drive the market growth. Furthermore, rise in trend of pharmaceutical companies participating in tactical collaborations to increase their product profiles has augmented the growth of the Japan myasthenia gravis treatment market.
However, high cost of treatment is expected to impede the market growth. In addition, the government stringent regulations pertaining to the approval of drugs in Japan hampers the market growth.
Conversely, rise in demand for biologic representatives and new platform treatments is expected to provide several opportunities for the growth of the market.
The Japan myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. By age group, the market is divided into below 55 years and above 55 years. Depending on distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers.
The Porter's five forces is a model which analyzes the competitive scenario of the industry and role of each stakeholder. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of new entrants, and the threat of substitutes and the competition among competitive rivalry. The market is expected to enable strong competition, as there are a multitude of players in the market. The threat of new entrants is low due to the high obstacle to entrance.
In Japan, pharmaceutical companies are focusing on new product advancements and R&D for the production of myasthenia gravis medications. Furthermore, businesses are investing heavily in R&D activities for creating new healing products for the disease. For instance, in 2019, Celgene Corporation launched the Natpara shot for myasthenia gravis in Japan. In addition, firms are focusing on broadening their product profile and offering solutions such as pharmacovigilance and telemedicine to increase their product offerings.
Furthermore, pharmaceutical businesses are focusing on pricing strategies for new and existing products to increase their market share. For instance, in 2018, Pfizer Inc. reduced the market price of its Botulism Antivenin in Japan to increase its sales. In addition, businesses are targeting end-users by launching awareness programs, such as the Myasthenia Gravis Recognition Week to acquire visibility in the market.
The Japan myasthenia gravis treatment market is expected to witness considerable growth in the upcoming years. The technical innovations and rise in prevalence of the disorder are expected to drive the market growth. The introduction of biomarkers for myasthenia gravis is anticipated to open up new avenues for the market in the near future.
Furthermore, increase in the application of Contract Research study Organizations (CROs) and professional tests are expected to boost the market growth during the forecast period. In addition, increase in the focus on the development of biosimilars is anticipated to provide remunerative opportunities for the growth of the market.
The Japan myasthenia gravis treatment market is anticipated to witness healthy growth during the forecast period owing to the presence of principals, technical growths, and increase in prevalence of the condition.
The introduction of unique treatments and the launch of awareness programs are expected to drive the market growth. Furthermore, the increase in product portfolios by focusing on pricing techniques and procurement activities are anticipated to offer lucrative opportunities for the market in the near future.
Key players included in the report are Astellas Pharma, GlaxoSmithKline, Takeda Pharmaceutical, Daiichi Sankyo, Teva Pharmaceutical Industries, Torii Pharmaceutical, UCB, Merck & Co., Pfizer, Genzyme Corporation
The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in Japan Myasthenia Gravis treatment Market.
- Assess and rank the top factors that are expected to affect the growth of Japan Myasthenia Gravis treatment Market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Detailed analysis of the Japan Myasthenia Gravis treatment Market segmentation assists to determine the prevailing market opportunities.
- Identify key investment pockets for various offerings in the market.
Japan Myasthenia Gravis Treatment Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 75 |
 By Age group |
|
 By Drug class |
|
 By Distribution channel |
|
 Key Market Players | Daiichi Sankyo, GlaxoSmithKline, Teva Pharmaceutical Industries, Takeda Pharmaceutical, UCB, Torii Pharmaceutical, Pfizer, Genzyme Corporation, Merck & Co., Astellas Pharma |
The Japan Myasthenia Gravis Treatment Market is estimated to reach $236.9 million by 2032
Company 1, Company 2, Company 3, Company 4, Company 5, Company 6, Company 7, Company 8, Company 9, Company 10 are the leading players in Japan Myasthenia Gravis Treatment Market
1. Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
2. Analyze the key strategies adopted by major market players in japan myasthenia gravis treatment market.
3. Assess and rank the top factors that are expected to affect the growth of japan myasthenia gravis treatment market.
4. Top Player positioning provides a clear understanding of the present position of market players.
5. Detailed analysis of the japan myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
6. Identify key investment pockets for various offerings in the market.
Japan Myasthenia Gravis Treatment Market is classified as by age group, by drug class, by distribution channel
Loading Table Of Content...
Loading Research Methodology...
